MedPath

Antenatal Corticoid Therapy for Late Preterm Babies

Not Applicable
Completed
Conditions
Transient Tachypnea
Hyaline Membrane Disease
Interventions
Registration Number
NCT00675246
Lead Sponsor
Instituto Materno Infantil Prof. Fernando Figueira
Brief Summary

This study aims to determine the effectiveness of antenatal corticosteroid therapy in late preterm babies. The investigators hypothesis is corticoid accelerates fetal lung maturation even after 34 weeks and reduces risk of respiratory distress syndrome and other neonatal morbidities.

Detailed Description

Late preterm babies have important morbidity when compared with term babies, with oxygen requirement and more days of hospitalization. If antenatal corticosteroid therapy is necessary for fetal lung maturation after 34 weeks, it remains to be established. The systematic review with metanalysis in Cochrane Library includes a small number of late preterm babies and no conclusion about effectiveness of corticoid therapy in this setting could be drawn. Our hypothesis is that antenatal corticosteroid therapy is effective to prevent respiratory disease and morbidity in late preterm babies and this study will be carried out to evaluate this question.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
320
Inclusion Criteria
  • Pregnancy between 34 and 36 weeks
  • Confirmed gestational age (LMP, USG)
  • Alive fetus
  • Imminent risk of preterm delivery
Read More
Exclusion Criteria
  • Multiple pregnancy
  • Major fetal malformations
  • Comproved fetal lung maturity
  • Maternal or fetal indication for immediate interruption of pregnancy
  • Maternal hemorrhagic syndromes (placenta previa, abruptio placenta)
  • Chorioamnionitis
  • Chronic use of corticosteroids
  • Previous use of corticosteroids for fetal lung maturation in the current pregnancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ABetamethasoneAntenatal corticoid therapy
Primary Outcome Measures
NameTimeMethod
neonatal respiratory distressneonatal period (28 days of life)
Secondary Outcome Measures
NameTimeMethod
neonatal deathneonatal period (28 days of life)
during of neonatal hospitalizationneonatal period (28 days of life)
neonatal sepsisneonatal period (28 days of life)
neonatal oxygen requirementneonatal period (28 days of life)

Trial Locations

Locations (1)

Instituto Materno Infantil Prof. Fernando Figueira

🇧🇷

Recife, Pernambuco, Brazil

© Copyright 2025. All Rights Reserved by MedPath